Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New gel could help heal wounds in rare skin disease

NCT ID NCT06917690

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a gel called Oleogel-S10 on skin wounds in people with inherited epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. The trial includes 6 Japanese children and adults with junctional or dystrophic EB. Participants apply the gel to wounds every few days for 45 days, with follow-up visits every two weeks. The goal is to see if the gel helps wounds close faster and is safe to use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oleogel-S10 (a topical gel)
What this could lead to
If successful, this gel could become a treatment option to help close and heal skin wounds in people with epidermolysis bullosa, reducing pain and infection risk.
What could go wrong
This is a small, early-phase trial with only 6 participants, so results may not apply to everyone. The gel may not work for all wound types, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 6 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 days and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female aged ≥ 21 days 2. Confirmed diagnosis of either JEB or DEB 3. Both biological parents and all 4 grandparents of Japanese descent 4. At least 3 EB wounds that meet the following criteria at the time of enrollment: * All are located outside of the anogenital region * All are distinguishable from any other wounds on the subject's body (separated by a minimum of 5 cm) * At least one has been present for a minimum of 21 days but less than 9 months AND is 10 cm2 to 50 cm2 in size * At least two have been present for a minimum of 21 days but less than 9 months AND/OR are 10 cm2 to 50 cm2 in size 5. A female subject must meet one of the following criteria: * If of childbearing potential, she must: 1. Have a negative pregnancy test result at Screening and Baseline Visits, AND 2. Agree to use one of the following highly reliable methods of contraception from the day of the informed consent signature until the day after the last Oleogel- S10 application. The following methods are acceptable: * Placement of an intrauterine device (IUD) or intrauterine releasing system (IUS) * Combined (both estrogen and progestogen) hormonal contraception (oral) associated with inhibition of ovulation, supplemented with a barrier method (preferably male condom) * Bilateral tubal occlusion * Sexual abstinence, defined as refraining from heterosexual intercourse during the entire study period * Partner vasectomy, provided that the partner is the sole sexual partner and has received medical verification of the surgical success * Be of non-childbearing potential, defined as one of the following: * Pre-menarche, OR * Post-menopausal (12 consecutive months of amenorrhea without an alternative medical cause), OR * Permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy (supporting evidence required) 6. Subject and/or subject's legal representative has been informed about the study, has read and understood the information provided, and has given written informed consent 7. Subject and/or subject's legal representative is able and willing to follow all study procedures and instructions Exclusion Criteria: 1. Hypersensitivity to Oleogel-S10 or any of its excipients 2. Diagnosis of EB subtypes simplex or Kindler EB 3. Receipt of systemic antibiotics for wound-related infections within 7 days prior to enrollment 4. Receipt of systemic or topical (on EB wounds) steroids within 30 days prior to enrollment Exceptions: Inhaled, ophthalmic, or mucosal applications, such as budesonide suspension for esophageal strictures 5. Receipt of immunosuppressive therapy or cytotoxic chemotherapy within 60 days prior to enrollment Note: Dupilumab to manage pruritis is allowed if the subject has been on a stable dose for more than 3 months prior to baseline 6. Receipt of systemic gene therapy for the treatment of inherited EB 7. Receipt of short-acting stem cell therapy (infusion of Muse cells, allogeneic adipocyte-derived MSC sheet (topically applied), TEMCELL (allogeneic MSCs, subcutaneous injection)) within 6 months prior to study enrollment 8. Receipt of topical gene therapy for the treatment of inherited EB (e.g., beremagene geperpavec) within 3 months prior to enrollment 9. Receipt of a JACE® skin graft on any of the target wounds 10. Current and/or former malignancy, including skin malignancies such as basal cell carcinoma and squamous cell carcinoma 11. Females: Pregnant or lactating, or of childbearing potential with a fertile male partner and unwilling to use a highly reliable method of contraception from the informed consent signature until study participation ends 12. Enrollment in any other interventional study or treated with any other investigational drug for any disease within 4 weeks prior to enrollment 13. Presence of any factor in the subject and/or legal representative that could interfere with study compliance, such as the ability to attend the scheduled study visits or to properly manage the dressing changes at home

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Collagen diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fukuoka Children's Hospital - Dermatology

    RECRUITING

    Fukuoka, Japan

  • Hokkaido University Hospital

    RECRUITING

    Sapporo, Japan

  • Kobe University Hospital

    RECRUITING

    Kobe, Japan

  • Kurume University Hospital

    RECRUITING

    Fukuoka, Japan

  • Niigata University Medical and Dental Hospital

    RECRUITING

    Niigata, Japan

  • Toho University Omori Medical Center

    RECRUITING

    Ōta-ku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.